Natural Killer Cell Cellular-based Therapeutic Options to Manage Acute Myeloid Leukemia: Prospects and Challenges
Oncology Advances · 2024
DOI: 10.14218/ona.2024.00013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Advances, 2024. Verfasst von Ogochukwu O. Izuegbuna. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Over the past decade, significant progress has been made in managing acute myeloid leukemia (AML). However, refractory disease and relapse continue to pose major challenges. These issues highlight the need for innovative therapeutic options to achieve deeper remission and effectively treat refractory and relapsed diseases, thereby improving survival rates. Natural killer (NK) cell-based therapies have emerged as a promising option. NK cells, a specialized population of innate lymphoid cells, exhibit inherent anti-viral and anti-cancer capabilities. Unlike T cells, NK cells do not require prior antigen sensitization to eliminate their target cells, enhancing their potential as immunotherapeutic agents. However, NK cells often exhibit dysfunction in patients with hematological malignancies. Revitalizing these cells represent another immunotherapeutic strategy. Various NK cell-based therapies have been explored in recent decades, particularly in managing AML. These therapies include chimeric antigen receptor-NK cell therapy, bispecific and trispecific NK cell engagers (bi-specific killer cell engager (BiKEs) and tri-specific killer cell engager (TriKEs), and cytokine-induced memory-like NK cells. These therapies are also associated with fewer adverse events, such as neurotoxicity. Despite their potential for clinical cancer management, challenges such as the in vivo expansion of NK cells remain unresolved. This review summarizes the biology of NK cells and the diverse NK cell-based therapies being developed for the potential management of AML, as evidenced in preclinical studies and clinical trials.
Zitieren
APA
Izuegbuna, O. O. (2024). Natural Killer Cell Cellular-based Therapeutic Options to Manage Acute Myeloid Leukemia: Prospects and Challenges. Oncology Advances. https://doi.org/10.14218/ona.2024.00013
Vancouver
Izuegbuna OO. Natural Killer Cell Cellular-based Therapeutic Options to Manage Acute Myeloid Leukemia: Prospects and Challenges. Oncology Advances. 2024. doi:10.14218/ona.2024.00013
BibTeX
@article{Izuegbuna2024,
author = {Izuegbuna, Ogochukwu O.},
title = {Natural Killer Cell Cellular-based Therapeutic Options to Manage Acute Myeloid Leukemia: Prospects and Challenges},
journal = {Oncology Advances},
year = {2024},
doi = {10.14218/ona.2024.00013}
}
EUVIMED